Patient Outcomes:: |
---|
After six months of treatment, 50% of the patients with severe anxiety disorders have a score of less than three on the Clinical Global Impression- Severity (CGI-S) scale. |
Experienced quality of life, as measured by the Manchester Short Assessment of Quality of Life (MANSA) scale, improved by 15 points for 75% of patients with a dual diagnosis. |
Social functioning, as measured by the Health of the Nation Outcome Scale (HONOS), improved by 2 points for 100% of patients with schizophrenia. |
Monitoring: |
At least 80% of the patients with anxiety disorders are monitored (every six weeks from the start of study and at least two times) using the Clinical Global Impression- Severity (CGI-S) scale. |
The quality of life of 100% of the patients with a dual diagnosis is monitored (every 12 weeks and at least two times during the study) using the Manchester Short Assessment of Quality of Life (MANSA) scale. |
The social functioning of 100% of the patients with schizophrenia is monitored at least two times using the Health of the Nation Outcome Scale (HONOS). |
Screening/assessment: |
Every month at least 4 out of 1000 patients suspected of anxiety disorders, are screened using the Four Dimensional Symptom Questionnaire (4DSQ). |
Of all patients with dual diagnosis, 100% are screened for psychopathology with the Health of the Nation Outcome Scale (HONOS). |